Last reviewed · How we verify
Ethylene Glycol Toxicity — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Antizol | FOMEPIZOLE | Par Pharm Inc | Antidote [EPC] | Alcohol dehydrogenase | 1997-01-01 | |
| Antizol | Antizol | Amgen | Alcohol dehydrogenase, Alcohol dehydrogenase |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Amgen · 1 drug in Ethylene Glycol Toxicity
- Par Pharm Inc · 1 drug in Ethylene Glycol Toxicity
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Ethylene Glycol Toxicity:
- Ethylene Glycol Toxicity treatment updates — RSS
- Ethylene Glycol Toxicity treatment updates — Atom
- Ethylene Glycol Toxicity treatment updates — JSON
Cite this brief
Drug Landscape (2026). Ethylene Glycol Toxicity — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/ethylene-glycol-toxicity. Accessed 2026-06-10.
Related
- Ethylene Glycol Toxicity full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing